Clinical Trial Update: Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating hematopoietic stem cell therapy for patients with refractory myasthenia gravis; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Hematopoietic Stem Cell Therapy

Snippet

Sponsor: Northwestern University | Conditions: Myasthenia Gravis | Phase 1 | Status: TERMINATED | Results posted: 2018-08-06